Focus less on pounds and more on the positive changes in how your body feels and functions
DiStefano, as well as Kavita Nair, PhD, Joseph Saseen, PharmD, and Gina Moore, PharmD, will specifically study The Rise of Compounded GLP-1 Weight Loss Medications: A Landscape Analysis of the Direct-To-Consumer Market. Their study will look at the rise in compounded GLP-1 products, (so-called Ozempic knock-offs) advertised and sold to consumers by telehealth platforms, weight loss clinics, and medical spas
Bottom line Retatrutide is a groundbreaking, next-generation triple G weight loss injection that mimics three gut hormones to suppress appetite and elevate metabolism, clearing a historic 2026 Phase 3 trial with a surgery-like 28.3% average weight loss
And when Novo Nordisk faced production issues, the decision to choose Eli Lilly's Mounjaro and Zepbound over Novo Nordisk's Wagovy became even easier